Table of Contents
ISRN Orthopedics
Volume 2012, Article ID 504151, 5 pages
Clinical Study

Efficacy and Tolerability of Clarema 1% Cream and Hirudoid 40000 U.APTT Gel in the Topical Treatment of Haematomas and/or Subcutaneous Haematic Extravasations

Sport Medicine and Traumatology Unit, Lucca General Hospital, 55100 Lucca, Italy

Received 12 September 2011; Accepted 17 October 2011

Academic Editors: K. Akeda and A. Combalía

Copyright © 2012 Tiziana Polieri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. T. Gallagher and M. Lyon, “Molecular structure of Heparan Sulfate and interactions with growth factors and morphogens,” in Proteoglycans: Structure, Biology and Molecular Interactions, M. V. Iozzo, Ed., pp. 27–59, Marcel Dekker, New York, NY, USA, 2000. View at Google Scholar
  2. R. V. Iozzo, “Matrix proteoglycans: from molecular design to cellular function,” Annual Review of Biochemistry, vol. 67, pp. 609–652, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. T. Gallagher and A. Walker, “Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides,” Biochemical Journal, vol. 230, no. 3, pp. 665–674, 1985. View at Google Scholar · View at Scopus
  4. A. M. Agrati et al., “Heparan sulfate: efficacy and safety in patients with chronic venous insufficiency,” Minerva Cardioangiologica, vol. 39, no. 10, pp. 395–400, 1991. View at Google Scholar
  5. L. Ganassin et al., “Evaluation of anti-thrombophilic properties of heparan sulfate in venous vascular pathology. A controlled clinical study versus active reference,” Minerva Cardioangiologica, vol. 39, no. 7-8, pp. 275–283, 1991. View at Google Scholar